8-K: Atara Biotherapeutics Announces $16 Million Registered Direct Offering

Atara Biotherapeutics has entered into an underwriting agreement for a $16 million registered direct offering of common stock and pre-funded warrants.

Summary

• Atara Biotherapeutics, Inc. has entered into an underwriting agreement for a registered direct offering.
• The offering includes 834,237 shares of common stock and pre-funded warrants to purchase up to 1,587,108 shares of common stock.
• The purchase price is $6.61 per share and $6.6099 per share underlying the pre-funded warrants.
• The exercise price of each pre-funded warrant is $0.0001 per share and they are exercisable immediately with no expiration date.
• The aggregate gross proceeds to the Company are expected to be approximately $16.0 million before deducting underwriting discounts, commissions, and offering expenses.
• The offering is expected to close on May 16, 2025.
• The company intends to use the net proceeds to fund its ongoing activities required to achieve the biologics license application (BLA) approval for tab-cel, and for working capital and other general corporate purposes.

Sentiment

Score: 6

Explanation: The sentiment is neutral. While the capital raise is necessary for the company's operations, it also involves dilution for existing shareholders. The success hinges on the company's ability to achieve BLA approval for tab-cel.

Positives

• The offering will provide Atara Biotherapeutics with additional capital to fund its operations and pursue BLA approval for tab-cel.
• The pre-funded warrants offer immediate exercisability, providing potential for additional capital in the near term.
• The company expects that cash, cash equivalents and short-term investments as of March 31, 2025, combined with $15.0 million in net proceeds received from the issuance and sale of the Securities pursuant to this Agreement, the cost reductions from the announced workforce reductions in January, March and May 2025 and the operating efficiencies resulting from the transition of tab-cel manufacturing responsibilities to Pierre Fabre, will enable the Company to fund its planned operations through the anticipated biologics license application (BLA) review period.

Negatives

• The offering will dilute existing shareholders' ownership.
• The company is selling shares and warrants at $6.61 and $6.6099 respectively, which may be perceived negatively if it's below market value.
• The company has agreed to certain restrictions on the issuance and sale of shares of the Companys securities for a period of 30 days following the Closing Date, subject to certain exceptions.

Risks

• The closing of the offering is subject to customary conditions and may not occur.
• The company's ability to obtain BLA approval for tab-cel is not guaranteed.
• The company's financial projections and use of proceeds are subject to change.
• There is no guarantee that the company will be able to achieve its planned operational efficiencies.

Future Outlook

The company intends to use the net proceeds from the offering to fund its ongoing activities required to achieve the biologics license application (BLA) approval for tab-cel, and for working capital and other general corporate purposes.

Industry Context

This offering reflects a common strategy for biotech companies to raise capital to fund ongoing research, clinical trials, and regulatory approval processes. The success of the offering will depend on investor confidence in Atara's pipeline and the potential of tab-cel.

Comparison to Industry Standards

• Comparable companies in the biotechnology sector, such as Juno Therapeutics (acquired by Celgene) and Kite Pharma (acquired by Gilead), have also utilized registered direct offerings to raise capital for their clinical programs.
• The terms of this offering, including the offering price and warrant structure, are within the typical range for similar transactions in the biotech industry.
• The use of proceeds for BLA approval and working capital is consistent with industry norms for companies in Atara's stage of development.

Management Changes

Stakeholder Impact

• Shareholders will experience dilution of their ownership.
• The company's employees will benefit from the continued funding of operations and the potential for BLA approval of tab-cel.
• The company's customers (patients) may benefit from the potential availability of tab-cel if BLA approval is obtained.
• The company's suppliers and creditors will benefit from the company's increased financial stability.

Next Steps

• The offering is expected to close on May 16, 2025, subject to customary closing conditions.
• The company will use the net proceeds to fund its ongoing activities required to achieve the biologics license application (BLA) approval for tab-cel, and for working capital and other general corporate purposes.

Key Dates

Keywords

Atara Biotherapeutics, registered direct offering, common stock, pre-funded warrants, tab-cel, biologics license application, BLA, capital raise, TD Securities, underwriting agreement